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were adapted respectively to screen independent risk factors of SMM, and a logistic 
model was set to predict the SMM by STATA 12.0. The areas under receiver operator 
characteristic (ROC) curve and agreement rate were used to evaluate the predic-
tion model. Results: Three kinds of unexpected surgeries, transfusion, hyster-
ectomy, ICU care, Multiple Organ Dysfunction Syndrome (MODS) were chosen as 
the outcomes of SMM by literature review and expert consensus. The rate of SMM 
was 2.30% in 33993 deliveries. All specified and substantially significant risk fac-
tors were divided in four aspects. Social characteristics included the hometown 
location of pregnant women. Pre-delivery characteristics were gestational weeks, 
multiparity, abnormal pregnancy history, PPH history and smoking. The coexisted 
diseases and complications of pregnancy were gestational hypertension, preec-
lampsia and eclampsia, other gestational hypertension diseases, placenta previa, 
placenta increta, hematological disease, cardiac disease and gynecological diseases. 
The delivery characteristics contained styles of onset labor, midwifery, episiotomy, 
macrosomia, fetal death, premature rupture of membrane, uterotonic treatment. 
The areas under ROC curve and agreement rate were 0.87 and 98.05% respec-
tively. ConClusions: SMM can reflect the severe degree of maternal outcomes 
indirectly, but also illustrate potential maternal health in a country or area by pro-
viding information to influence the delivery of health services and health policy. 
Our model specified dozens of risk factors and had considerably higher value of 
ROC area and agreement rate. We will perform the prospective research to predict 
and prevent the SMM in future.
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AbstRACt obJeCtiVes: The present study is a meta-analysis of clinical studies 
conducted to evaluate the efficacy of oximes in the treatment of organophospho-
rus (OP) intoxicated patients. Methods: PubMed, Scopus, Google Scholar, and 
clinicaltials.gov were searched for studies investigated the effects of oximes in the 
treatment of OP poisoning. Mortality, intermediate syndrome, intensive care unit 
(ICU) admission rate, and intubation rate were the key outcomes of interest. Data 
were searched in the time period of 1966 through December 2013. Results: Ten 
studies (nine clinical trials and one historical cohort) that met our criteria were 
included in the analysis. Pooling of data showed that relative risk (RR) of need for 
intubation in OP poisoning for eight included trials comparing oximes to placebo 
was 1.27 with 95% CI= 0.73 to 2.23 (P= 0.4). RR of only one observational study 
was 1.57 (95% CI= 0.79 to 3.2, P> 0.05). The summary of RR for mortality rate in 9 
studies was 0.38 (95% CI= 0.65 to 2.97, P= 0.41) and for one observational study 
was 1.33 (95% CI= 0.54 to 3.29, P> 0.05). The RR for ICU admission rate in OP poi-
soning for three trials comparing oximes to placebo was2.12 with 95% CI= 0.89 to 
5.03 (P= 0.09). For only one observational study, RR was 0.81 (95% CI= 0.49 to 1.25, 
P> 0.05). For intermediate syndrome, while the RR of only trial comparing oximes 
with placebo was 1.89 (95% CI= 1.27 to 2.91, P< 0.05) while for only one observa-
tional study, it was 1.43 (95% CI= 0.7 to 2.96, P> 0.05). ConClusions: According 
to these data, oximes beneficence in OP poisoning is unclear and if administered, 
great caution must be exercised because of increase in ICU admission rate and 
incidence of intermediate syndrome. KeywoRds: Organophosphorus, oxime, 
poisoning, meta-analysis.
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obJeCtiVes: Vaginal atrophy is a silent epidemic that affects up to 50%-60% of 
postmenopausal women. Local,low-dose estrogen preparations are considered 
first-line pharmacologic treatment. For women concerned about hormone use 
a number of over-the-counter (OTC) vaginal moisturizer and lubricant products 
are considered first-line nonhormonal treatments. It has been reported that vita-
min E vaginal gel improved the symptoms of volvovaginal atrophy However, oral 
vitamin E has never been well tested in a randomized clinical trial for efficacy 
against vaginal atrophy. Therefore the objective of this study is to assess the 
effect of vitamin E on the vaginal maturation index (VMI) of post menopausal 
women. Methods: Participants in this placebo-controlled randomized cross over 
trial were 60 menopausal women who 4-12 months passed from their menopause. 
After randomization the women were given medication blister pack cards that 
contained an 8-week supply of study medication (400IU of vitamin E or placebo 
daily). Following 1-week no treatment , baseline period, the first group received 
one vitamin E soft gel daily (400IU dl-Alpha-tocopheryl acetate) while the second 
group received placebo for four weeks. In order to eliminate the carry over effect 
of cross over trial, one week washout was considered. Then the medication was 
reversed for each group and the study was continuing for another four weeks.
Vaginal maturation index of the women before any intervention and after the 
first and second stage of treatment was evaluated. Results: The study groups 
were homogeneous regarding age, BMI, time since menopause, educational and 
job status. No statistically significant differences were observed in the percent-
age of superficial, intermediate and parabasal cells within the groups at baseline 
and after the first and second stage of treatment. ConClusions: Based on our 
trial treatment with vitamin E for 4 weeks has no effect on the maturation of the 
vaginal epithelium in postmenopausal women.
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domestic one, which also denoted COBAS test to be a less costly and more effec-
tive / dominant measure. In addition, sensitivity analysis showed the result was 
not sensitive to main indicators, including test price, week-4 and week-12 treat-
ment response rate, week-4 and week-12 false negative rate of domestic test, SVR 
rate of 24-week treatment for cEVR, and proportion of non-EVR in RNA positive in 
12th week. ConClusions: Compared with domestic HCV RNA test, for the short 
term treatment course, COBAS test can identify RVR & EVR more accurately, make 
more appropriate decisions of course period and have more patients achieve SVR. 
And in long term perspective, COBAS test plus appropriate course of treatment can 
prolong patient’s life year, improve patient’s life quality as well as decrease total 
medical expense due to less disease progress.
gasTroInTesTInal dIsorders – Health care use & Policy studies
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obJeCtiVes: Inappropriate utilization of proton pump inhibitors (PPI) and H2-
receptor antagonists (H2RA) in inpatients is prevalent, but poorly defined. We 
undertook a rigorous national audit to allow the standardization of grading system 
for appropriate use. Methods: Medical and demographic data were collected for all 
in-patients receiving a PPI or H2RA.Regimens reviewed included intravenous bolus 
PPI or H2RA (IVb), intravenous high dose continuous infusion PPI or H2RA (IVci = 
bolus followed by ci), and oral PPI or H2RA (PO); and were categorized as Endorsed 
or Not Endorsed [N-E]. Multivariate modeling was performed to assess predictors 
of E and N-E use. Results: Over 6 months, 1720 patients (age: 64.0±16.7 y, 43% 
women) receiving 2890 drug regimens were included from 21 Canadian institutions. 
28% were taking a PPI and 7% an H2RA before admission. 95% of in-hospital drug 
regimens used a PPI and only 5% a H2RA. 32% of drug regimens were endorsed. 
Proportions for E and N-E uses were 28.0 [25.5,30.7] and 72.0 [69.3-74.5], 18.2 [15.1-
21.7] and 81.8 [78.3-84.9], and 42.9 [40.0, 45.8] and 57.1 [52.2, 60.0] for IVb, IVci, and 
PO respectively. The most common indication was upper GI bleeding (70% of IVci, 
79% N-E; 18% of IVb, 69% N-E; 25% of PO regimens, 77% N-E). Stress ulcer prophylaxis 
was the prescribing indication in 8% of IVb (94% N-E), and 6% of oral (88% N-E). 
Independent predictors of E were suspicion of UGIB (for IVci and PO regimens), time 
of drug administration (for IVci and IVb), and sex (for IVci). ConClusions: Existing 
consensus recommendations provided no guidance as to appropriateness of use in 
up to 40% of regimens. Endorsed use was noted in only 28% of IVb, 18% of IVci, and 
43% of PO regimens. These data will help guide future guideline recommendations 
to optimize in-hospital prescribing of acid suppressants.
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obJeCtiVes: Polypharmacy has been associated with functional decline and 
adverse outcomes in vulnerable population and with an increased risk of Adverse 
Drug Events (ADE), particularly in fragile patients such as the elderly with complex 
medical conditions.Aim of this observational study was to describe and evalu-
ate ADE in patients with polypharmacy by a digital health service that prevents 
Drug-Drug Interactions (DDI) using the social security number (SSN). Methods: 
A cohort of 369 patients was identified through a closed loop, fully automated 
system that records and updates all the drugs taken during therapy cycle/s by spe-
cifically designed software interfaces loaded on Information and Communication 
Technology programs of the network.The tool was designed to support General 
Physicians in clinical decisions, providing them information about prescribed 
drugs/over the counter (OTC)/herbs, detailing dosage, comorbidity, number of 
packages and pills per package, prescription/purchase date. Results: About 30% 
of patients shown 1 comorbidity and 11.8% 2 or more. Cardiovascular diseases 
(22.7%) represented the most frequent comorbidity, followed by musculoskeletal 
pathology (13.6%), diabetes (8.6%), cancer (5.1%), and depression (4.8%).The Charlson 
Comorbidity Index was 0 in 65.2%, 1 in 25.7%, 2 in 7.0% and 3 to 4 in 2.1%. A total of 
67 patients (mean age 72 years; 52.2% women) had at least 1 DDI. About 50% (N = 
33) had up to 2 DDIs, 25% from 3 to 7 DDIs and 25% ≥ 8 (from 9–74 DDIs per person). 
A total of 501 DDIs were identified: the severity was low in 35.5%, moderate in 
59.7% and high in 4.8%. The top 10 drugs involved in DDI were: acetylsalicylic acid 
(ASA), hydrochlorothiazide, ibuprofen, diclofenac, digoxin, nebivolol, pantoprazole, 
ramipril, furosemide and nimesulide. ConClusions: ICT technologies are useful 
to timely identify DDIs of clinical relevance and the drugs most frequently involved.
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obJeCtiVes: To set a model to predict the Severe Maternal Morbidity (SMM) 
and specify the risk factors based on a registered study in Sichuan province, 
China. Methods: Overall 33993 deliveries of 8 hospitals in Sichuan province of 
China were consecutively collected between January 1, 2009, and December 31, 
2010 in our database. The forward and backward stepwise regression methods 
